PMP22 and Charcot-Marie-Tooth disease type 1A: In contrast, we here observed that PXT3003 short-term treatment downregulated Pmp22 overexpression, a potential target for other preclinical trials in CMT1A rats [15,34,35,37], as demonstrated in two different peripheral nerves.